18 hasil untuk "Fernando Perretta"
Menampilkan 1–18 · 1,24 detik · RSS
-
Artikel Jurnal
Case Report: Fabry cardiomyopathy associated with a novel truncating GLA variant, c.837_838delinsAT, p.(Gln280Ter)
We report the comprehensive clinical characterization of a woman with Fabry disease (FD) carrying a previously unreported truncating GLA variant, c.837_838delinsAT, p.(Gln280Ter). The patient, a 52-year-old woman with longstanding hypertrophic cardiomyopathy, was referred to a specialized Fabry…
-
Artikel Jurnal
Fabry disease. A potential pitfall A family with a novel intronic mutation
Fabry disease is a genetic disorder characterized by the accumulation of globotriaosylceramide in cell lysosomes resulting from an X-linked deficiency of α-galactosidase A activity. It presents with multiorgan manifestations, including progressive renal disease, cardiomyopathy and premature demise…
-
Artikel Jurnal
Vascular disease in male patients with Fabry disease on hemodialysis: a retrospective cohort study in Argentina
Introduction: Vascular events (VE), both cardiovascular (CVD) and cerebrovascular (CVA), are the main cause of death in patients with Fabry disease (FD). The aim of this study was to describe the occurrence of VE in patients with FD and end-stage renal disease (ESRD) on hemodialysis during…
-
Artikel Jurnal
Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina
Nephropathy is one of the major complications of Fabry Disease (FD) and mainly includes reduced glomerular filtration rate (GFR) and proteinuria. Despite the frequency, scarce information exists regarding the frequency of CKD as well as other related complications in FD patients in Argentina. The…
-
Artikel Jurnal
Nefropatía por enfermedad de Fabry. Rol del nefrólogo y variables clínicas asociadas al diagnóstico
Resumen: Antecedentes: La detección temprana de la nefropatía por enfermedad de Fabry es de interés, pues su tratamiento es más eficaz en estadios precoces. Ha sido estudiada por biomarcadores moleculares y tisulares, pero estos poseen desventajas que dificultan su uso rutinario. El propósito del…
-
Artikel Jurnal
Fabry nephropathy. Role of nephrologist and clinical variables associated with the diagnosis
Background: The early detection of Fabry nephropathy is of interest to us. Its treatment is more effective in early stages. It has been studied by analysing molecular and tissue biomarkers. These have certain disadvantages that hinder its routine use. The aim of this study is to describe the role…
-
Artikel Jurnal
New Drugs Available for Fabry Disease
Background: Fabry disease (FD) is an X-linked genetic condition caused by variants in the GLA gene, leading to a deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A) and the accumulation of complex glycosphingolipids such as globotriaosylceramide (Gb3) and globotriaosylsphingosine…
-
Artikel Jurnal
Early Renal Involvement in a Girl with Classic Fabry Disease
Fabry disease is an X-linked lysosomal storage disorder resulting from the deficiency or absence of the enzyme alpha galactosidase A; this defect leads to the systemic accumulation of globotriaosylceramide and its metabolites. Organic involvement in men is well known, but in women it is…
-
Artikel Jurnal
Major Organic Involvement in Women with Fabry Disease in Argentina
Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from the deficiency or absence of the alpha galactosidase A enzyme. Organic involvement in men is well known, but in women it is controversial, partly due to the random X-chromosomes inactivation (Lyon hypothesis). The aim of…
-
Artikel Jurnal
CONTROVERSIAS EN LA INDICACIÓN DE TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE FABRY EN LA ARGENTINA
Introducción. Los criterios de indicación de tratamiento en enfermedades lisosomales son motivo de controversia. La detección temprana de síntomas posibilitaría un inicio temprano de tratamiento y mejoraría el pronóstico de pacientes afectados, aunque esto es dificultoso, por su presentación…
Juga tersedia di: DOAJ
-
Artikel Jurnal
Fabry nephropathy. Urinary expression of podocyte proteins mRNA and microRNAs in non-albuminuric patients
Introducción: Determinar los mecanismos involucrados en etapas tempranas del daño renal por Fabry es de utiidad para: (i)incrementar la probabilidad de eficacia terapéutica y, (ii) permitir el desarrollo de nuevas terapias. En el presente estudio, una población de pacientes Fabry sin albuminuria…
-
Artikel Jurnal
Urinary VEGF-A165b mRNA expression in Fabry disease: Pilot study
Background: Vascular endothelial growth factor (VEGF) is associated with renal pathogenesis of Fabry disease (FD). Proteomic studies have demonstrated that circulating levels of VEGF are higher in young FD patients compared with controls and an overexpression of tissue VEGF in animal models of…
-
Artikel Jurnal
Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by loss of function mutations in the GLA gene at Xq22 with subsequent functional deficiency of alpha-galactosidase A, resulting in the accumulation of globotriaosylceramide (GL-3 or Gb3) in multiple cells types throughout the body…
-
Artikel Jurnal
Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort
Fabry disease (FD) is a multisystem lysosomal storage disorder induced by genetic variants in the alpha-galactosidase A (αGalA) gene. Some FD patients have GLA variants with a reduction in overall αGalA enzymatic activity due to mutated proteins with reduced stability, caused by protein misfolding…
-
Artikel Jurnal
Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards
Background: Fabry disease (FD) is an X-linked lysosomal sphingolipidosis. It is caused by pathogenic variants in the GLA gene with a consequent deficiency of the enzyme α-galactosidase A, resulting in the pathological accumulation of glycolipids - mainly globotriosyl ceramide (GL-3, GB3) and its…